About UsBellicum Pharmaceuticals is a privately held biotherapeutics company headquartered in Houston, Texas. Founded in 2004 by Baylor College of Medicine Professors Kevin Slawin, MD and David Spencer, PhD, to commercialize Chemical Induction of Dimerization (CID) technology, the company became fully operational in 2006 with the addition of CEO Tom Farrell, completion of a seed financing, and execution of a core license agreement with ARIAD Pharmaceuticals. We have two programs in clinical development, and have assembled a world class team of advisors and consultants. |
